PFE · News · 20260923N

Competition and Market Share

PFIZER INC · 2026-09-23 · Importance 17 · Surprise 24

BridgeBio reported that its acoramidis product, marketed as Attruby, outperformed Pfizer's tafamidis product Vyndamax in a real-world study. Attruby received U.S. Food and Drug Administration approval in November 2024 for transthyretin cardiac amyloidosis. The reported comparative result creates potential competitive and market-share pressure for Pfizer in cardiovascular amyloidosis treatment.

Key facts

• Pfizer's stock has risen 23.9% over the past year. source
• Pfizer has a P/E ratio of 36.7x and it trades above the pharmaceuticals industry average. source
• Pfizer trades under $50 a share. source